Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug

Orexigen said Thursday it has eliminated 23 jobs, or about 40 percent of its workforce, a little more than a week after the FDA shot down Orexigen’s application to start selling its first product, a new drug for obesity.
Xconomy